Genenta Science S.p.A.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $36.4M
- Price
- $0.755
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.28%
- Volume
- 23.2K
About
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.
Quick stats
Shares outstanding48.2M
Computed float15.7M
Float / shares32.5%
Cash runway (months)32
Key info
SectorIndustrials
IndustryAerospace & Defense
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001838716
Websitehttps://www.genenta.com
AI Summary
AI-generated1/7
minorbullishoperations update
Sòphia High Tech Flight Hardware on Board VEGA-C VV30 as the European Launcher Carries Sentinel-3C and FLEX into Orbit
Genenta Science (Nasdaq: GNTA), evolving into Saentra Forge, said Sòphia High Tech — the Italian aerospace manufacturer in which Genenta made a strategic 2026 investment — built the Spring Assembly aboard the VEGA-C VV30 rocket that lifted off September 15, 2026 from Europe's Spaceport in Kourou, French Guiana.
The Spring Assembly sits in the interstage between the Zefiro 40 second stage and Zefiro 9 third stage and executes controlled stage separation; Sòphia HT has produced the component in serial production since 2018. VV30 carried the Copernicus Sentinel-3C and ESA's FLEX Earth-observation satellites, both built by Thales Alenia Space.
CEO Pierluigi Paracchi framed the flight as validation of the flight-qualified Italian engineering platform Genenta is assembling as it pivots from biotech into an aerospace, defense, national security and biotechnology consolidator.
The release discloses no financial figures, contract values, or revenue contribution; the Saentra Forge name change remains subject to shareholder approval and forward-looking statements cite risk around closing the Sòphia High Tech transaction.
Red flags
- Saentra Forge name change is still subject to shareholder approval
- Forward-looking statements flag risk that the Sòphia High Tech transaction may not close
- Promotional release with no financial metrics, contract values, or disclosed revenue contribution from the aerospace pivot
- Company is mid-transition from clinical-stage biotech into aerospace/defense consolidation — execution and funding risk